ZA919977B - Use of human igf-i - Google Patents

Use of human igf-i

Info

Publication number
ZA919977B
ZA919977B ZA919977A ZA919977A ZA919977B ZA 919977 B ZA919977 B ZA 919977B ZA 919977 A ZA919977 A ZA 919977A ZA 919977 A ZA919977 A ZA 919977A ZA 919977 B ZA919977 B ZA 919977B
Authority
ZA
South Africa
Prior art keywords
treatment
prevention
human igf
cardiac
medicament
Prior art date
Application number
ZA919977A
Other languages
English (en)
Inventor
Peter Gluckman
Gluckman Peter
Anna Skottner
Skottner Anna
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of ZA919977B publication Critical patent/ZA919977B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA919977A 1991-01-11 1991-12-19 Use of human igf-i ZA919977B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100099A SE9100099D0 (sv) 1991-01-11 1991-01-11 Use of growth factor

Publications (1)

Publication Number Publication Date
ZA919977B true ZA919977B (en) 1992-09-30

Family

ID=20381598

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA919977A ZA919977B (en) 1991-01-11 1991-12-19 Use of human igf-i

Country Status (16)

Country Link
US (1) US5434134A (es)
EP (2) EP0501937B1 (es)
JP (1) JP3566283B2 (es)
AT (1) ATE150316T1 (es)
AU (1) AU657729B2 (es)
CA (1) CA2099257A1 (es)
DE (1) DE69218406T2 (es)
DK (1) DK0566641T3 (es)
ES (1) ES2101833T3 (es)
GR (1) GR3023614T3 (es)
IE (1) IE914392A1 (es)
IL (1) IL100585A (es)
NZ (1) NZ241108A (es)
SE (1) SE9100099D0 (es)
WO (1) WO1992011865A1 (es)
ZA (1) ZA919977B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996010401A1 (en) * 1994-10-04 1996-04-11 Emory University Methods for regulation of insulin-like growth factor i receptor
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
GB9605124D0 (en) 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
EP1566180A3 (en) * 1996-08-30 2007-08-08 Eli Lilly & Company Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US6300271B1 (en) * 1998-05-18 2001-10-09 Phillips Petroleum Company Compositions that can produce polymers
CA2335391A1 (en) * 1998-10-02 2000-04-13 Kenneth Walsh Akt compositions for enhancing survival of cells
US7368420B1 (en) 1998-10-02 2008-05-06 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Akt compositions for enhancing survival of cells
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
SE9901634D0 (sv) * 1999-05-05 1999-05-05 Sahltech Ab Treatment of myocardial infarction with a substance related to the growth hormone axis
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20110091428A1 (en) * 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US20020061587A1 (en) 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20020082215A1 (en) * 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
CN100439397C (zh) 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1841443A4 (en) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc METHOD AND SYSTEM FOR TREATING HEART ERRORS
JP2008529968A (ja) * 2005-02-08 2008-08-07 国立循環器病センター総長 インスリン様成長因子−１（ｉｇｆ−１）を使用する慢性重症心不全を処置するための新規方法
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
CA2743697A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2245140A2 (en) * 2007-11-30 2010-11-03 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2227238A2 (en) 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
CN110812369A (zh) * 2018-08-10 2020-02-21 浙江楚沅生物科技有限公司 用于治疗组织坏死或改善心脏功能的药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272649A (en) * 1979-04-09 1981-06-09 Williams Electronics, Inc. Processor controlled sound synthesizer
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects

Also Published As

Publication number Publication date
JPH06504286A (ja) 1994-05-19
IL100585A0 (en) 1992-09-06
EP0501937A1 (en) 1992-09-02
CA2099257A1 (en) 1992-07-12
DK0566641T3 (da) 1997-10-06
DE69218406T2 (de) 1997-07-10
IE914392A1 (en) 1992-07-15
WO1992011865A1 (en) 1992-07-23
ATE150316T1 (de) 1997-04-15
GR3023614T3 (en) 1997-08-29
AU657729B2 (en) 1995-03-23
JP3566283B2 (ja) 2004-09-15
ES2101833T3 (es) 1997-07-16
SE9100099D0 (sv) 1991-01-11
EP0566641B1 (en) 1997-03-19
EP0501937B1 (en) 1997-03-19
DE69218406D1 (de) 1997-04-24
US5434134A (en) 1995-07-18
IL100585A (en) 1997-04-15
AU1166992A (en) 1992-08-17
NZ241108A (en) 1997-06-24
EP0566641A1 (en) 1993-10-27

Similar Documents

Publication Publication Date Title
GR3023614T3 (en) Use of human igf-i
GR3036901T3 (en) Treatment of partial growth hormone insensitivity syndrome
DE69535491D1 (de) Niedermolekulare Peptide zur Stimulation der Sekretion von Wachstumshormonen
FI932385A0 (fi) Behandling av osteoporos genom anvaendning av somatoliberin (GRF) i en kombination med paratyreoideahormon (PTH)
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
EP0464022A4 (en) Insulinotropic hormone
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
EP0703785A4 (en) METHODS FOR TREATING MUSCLE DISEASES AND MUSCLE DISORDER
RU94031209A (ru) Применение бисфосфонатов и гормона околощитовидной железы для лечения остеопороза
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
DE3481306D1 (de) Biologisch wirksame peptide strukturell mit regionen von wachstumshormonen in verbindung stehend.
DK0585397T3 (da) Bombesinanaloger
CA2334941A1 (en) Tnf-derived peptides for use in treating oedema
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
DE69326122D1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
YU40398A (sh) Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
ATE246511T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms
IL145403A0 (en) Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients
IL101620A0 (en) Superactive grf analogs
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
RU93058426A (ru) Антогонист галанина, способ его получения, пептид, фармацевтический состав и способ лечения
UA10248A (uk) Спосіб лікування ішемічної хвороби серця на фоні цукрового діабету
MX9707904A (es) Analogos del factor de liberacion de la hormona del crecimiento.